Related Experiment Video
Updated: Jun 27, 2026
09:58
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Differential splicing, disease and drug targets
O Villate1, A Rastrojo, R López-Díez
1Centro de Biología Molecular Severo Ochoa (CBMSO), CSIC, Campus Cantoblanco, 28049 Madrid, Spain.
Infectious Disorders Drug Targets
|December 17, 2008
Summary
Alternative splicing (AS) generates protein diversity but altered isoforms can cause disease. This study reviews differential splicing, associated pathologies, and therapeutic strategies to restore normal mRNA expression.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Alternative splicing (AS) is a key mechanism generating proteomic diversity from a limited genome.
- Dysregulation of AS contributes to various human pathologies.
- Understanding AS is crucial for developing targeted therapies.
Purpose of the Study:
- To elucidate the role of differential splicing in disease.
- To catalog diseases linked to aberrant mRNA isoforms.
- To review current and emerging therapeutic strategies for splicing modulation.
Main Methods:
- Review of scientific literature on alternative splicing.
- Analysis of disease mechanisms driven by splicing alterations.
- Compilation of therapeutic approaches targeting splicing.
Main Results:
- Identified numerous pathologies associated with altered splicing isoforms.
- Highlighted the complexity of targeting specific isoforms due to drug effects on multiple variants.
- Discussed strategies for both restoring canonical splicing and promoting beneficial aberrant splicing.
Conclusions:
- Alternative splicing is a significant source of genetic variation and disease.
- Therapeutic strategies must carefully consider the impact on various mRNA isoforms.
- Targeting splicing offers promising avenues for treating diverse diseases.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:32RNA Splicing
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
01:32RNA Splicing
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
02:18Alternative RNA Splicing
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...